Form 497VPU AuguStar Variable Accoun
Tweet
Share
E-mailONcore Series of Variable Annuities
AuguStarSM Life Insurance Company
AuguStarSM Variable Account A
Supplement dated November 25, 2024
to the Prospectuses and
Updating Summary Prospectuses dated April 30, 2024
The following supplements the prospectuses and updating summary prospectuses dated April 30, 2024, as previously supplemented. Please read this supplement in conjunction with your prospectus and updating summary prospectus and retain it for future reference.
Appendix A – Funds Available Under the Contract
On or about November 25, 2024, the portfolios listed below removed their subadvisers, updated their fees, and changed their names. Appendix A is revised, effective upon such changes:
| Type/ Investment Objective |
Fund and Adviser/Subadviser
|
Current Expenses
|
Average Annual Total Returns (as of 12/31/23) | ||
| 1 year | 5 year | 10 year | |||
|
Allocation
|
AVIP Constellation Dynamic Risk Balanced Portfolio
Adviser: Constellation Investments, Inc. |
0.88% | 12.90% | 8.97% | N/A |
| Allocation |
AVIP Constellation Managed Risk Balanced Portfolio
Adviser: Constellation Investments, Inc. |
0.65% | 13.89% | N/A | N/A |
| Allocation |
AVIP Constellation Managed Risk Moderate Growth Portfolio
Adviser: Constellation Investments, Inc. |
0.65% | 16.15% | N/A | N/A |
| Allocation |
AVIP Constellation Managed Risk Growth Portfolio Adviser: Constellation Investments, Inc. |
0.66% | 19.62% | N/A | N/A |
Any changes made in Appendix A above are incorporated throughout your documents.
1
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/25/2026
- Wall Street closes lower to end rocky week
- Meta's capital-raising plans expose a major weakness in the AI boom
- Oil prices jump $3 on Houthi attacks, oil spill, highest settlement since April
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Xencor Presents Phase 1 Dose Selection Data for XmAb819, a Potential First-in-Class ENPP3 x CD3 Bispecific T-Cell Engager, in Development for Patients With Advanced Clear Cell Renal Cell Carcinoma and
- Dogecoin Price Prediction: New Dogecoin Labs Could Lift DOGE From $0.08, but Pepeto Looks Like Early DOGE
- Cryptocurrency News: $431M in Bets Wiped Out in a Day as Pepeto Buyers Chase Gains Like Ethereum’s First Holders
Create E-mail Alert Related Categories
SEC FilingsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
